Skip to content

SG&A at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62B+2.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$647.7M+2.3%
Gilead Sciences logo
Gilead SciencesGILD
$1.45B+15.3%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$38.68M+126%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$48.3M+16.3%
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's SG&A?
Precigen (PGEN) reported SG&A of $21.05M in Q1 2026.
How has Precigen's SG&A changed year-over-year?
Precigen's SG&A increased by 70.3% year-over-year, from $12.36M to $21.05M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.